Across TCGA pan-cancer cohorts, SRMP2 RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of SRMP2’s most consistent transcriptional readouts.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where SRMP2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SRMP2 is over-expressed in tumor.
HNSC are the cancer types where SRMP2 tumor–normal differential expression is most reproducible.